Nuclera Secures €74 Million in Series C Funding for eProtein Discovery System

Nuclera, a BioTech company based in Cambridge, has announced a €10 million ($12 million) financing extension, bringing its total Series C funding to €74 million ($87 million). The funding round was led by Elevage Medical Technologies and Jonathan Milner, with participation from existing investors British Business Bank and GK Goh. The investment will support the integration of antibody expression and binding validation capabilities into Nuclera’s eProtein Discovery benchtop system.

According to Dr. Michael Chen, CEO and co-founder of Nuclera, the financing signifies the company’s momentum in expanding eProtein Discovery into the biologics R&D segment. Nuclera aims to provide scalable, high-quality datasets to power AI models in biologics discovery, positioning itself as a foundational platform for protein and antibody engineering.

In parallel with Nuclera’s funding extension, there is sustained investor interest in European BioTech platforms specializing in protein engineering, biologics, and AI-enabled discovery. Companies like Avenue Biosciences, Tubulis, NanoPhoria Bioscience, and Latent Labs have secured significant funding for their innovative approaches to biologics R&D.

Dr. Michael Wasserman, Chief Operating Officer of Elevage Medical Technologies, commended Nuclera’s progress in expanding the capabilities of the eProtein Discovery platform. Elevage continues to support Nuclera as it evolves into a key player in protein and antibody engineering, facilitating accelerated discovery timelines and smoother drug development processes.

Established in 2013, Nuclera’s mission is to accelerate discovery by providing researchers with rapid access to high-quality functional proteins essential for drug discovery research. The eProtein Discovery benchtop system combines cell-free expression systems, digital microfluidics, and robust screening data to enable scientists to perform protein screening, characterization, and expression in-house.

Nuclera’s eProtein Discovery system reportedly reduces the time, cost, and uncertainty associated with protein expression and purification. Researchers can generate soluble, purified proteins for functional testing in under 48 hours, significantly speeding up workflows compared to traditional methods.

Dr. Jonathan Milner, Chairman of the Nuclera Board of Directors, highlighted the company’s success in membrane proteins and microfluidic expertise, positioning Nuclera to transform antibody development workflows. The expansion of eProtein Discovery with antibody-specific capabilities addresses the industry’s need for scalable, high-quality datasets to power AI-driven research in biologics discovery.

Since its previous Series C financing, Nuclera has enhanced its eProtein Discovery capabilities, expanded its global footprint, and collaborated with Cytiva to accelerate protein production processes. The installation of the eProtein Discovery system at Domainex has streamlined protein production services and validated its commercial and scientific impact.

In conclusion, Nuclera’s strategic advancements in eProtein Discovery and antibody-specific capabilities demonstrate its commitment to revolutionizing protein and antibody engineering in the biologics discovery landscape. The company’s innovative approach and collaborations position it as a key player in accelerating therapeutic discovery timelines and enhancing the drug development process. Sure! Here is the transformed content in pure HTML format: